We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Technique Designs Nucleic Acid Probes to Detect Rapidly Mutating Bacteria and Viruses

By LabMedica International staff writers
Posted on 16 Feb 2023

The COVID-19 pandemic has shown that the microbes responsible for some infections can rapidly mutate into variants which evade detection and treatment. More...

Now, researchers have developed a technique called AutoPLP that designs nucleic acid probes to help quickly, accurately and easily detect new variants of pathogens which can be hard to trace. This could help prevent infections that have the potential to spread quickly due to these dangerous variants.

Several diagnostics like the ones based on the polymerase chain reaction (PCR) detect pathogens by analyzing genetic material. Rolling circle amplification (RCA) works similarly but eliminates the need for complex temperature cycling unlike PCR. Both the approaches need nucleic acid probes with sequences that match those of the target pathogen in specific locations, although RCA utilizes highly specific “padlock probes” (PLPs). When a pathogen mutates, there is also a change in its genetic sequence, forcing researchers to keep redesigning their probes. So, researchers from the Indian Institute of Technology (IIT) Madras (Chennai, India) set out to create a tool that could automatically design these PLPs, as well as systematically take into account all the required technical parameters simultaneously to make the overall process easier and more robust.

The new tool, a computer program termed AutoPLP has been named after the PLPs it designs. The program takes the genome sequences of similar pathogens as input and runs a series of analyses and database searches, outputting a set of customized PLP sequences. Using the program, the researchers designed probes against the rabies virus and Mycobacterium tuberculosis. In the case of the rabies virus, AutoPLP targeted three genes, yielding probes with a higher and narrower range of melting temperatures as compared to those in the literature. In the case of M. tuberculosis, the team designed 13 probes that specifically targeted the two genes responsible for drug-resistant strains with the program. According to the researchers, the new tool could speed up the discovery of new pathogen variants, thus helping fight them rapidly and effectively through the use of precise molecular diagnostics.

Related Links:
IIT Madras


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.